Reprint

Novel Approaches for the Delivery of Anti-HIV Drugs

Edited by
May 2020
208 pages
  • ISBN978-3-03921-900-1 (Paperback)
  • ISBN978-3-03921-901-8 (PDF)

This book is a reprint of the Special Issue Novel Approaches for Delivery of Anti-HIV Drugs that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

HIV/AIDS continues to be one of the most challenging individual and public health concerns of the present day. According to the UNAIDS, nearly 38 million individuals were living with the infection by the end of 2018, while 1.7 million new cases occurred during that same year. In spite of the numerous advances in the development and delivery of antiretroviral agents, both for treatment and prevention, several challenges remain. This book includes original research and review articles on innovative strategies and approaches for the formulation and delivery of anti-HIV drugs, including genetic material and other biopharmaceuticals. Different local and systemic delivery strategies are addressed based on different technologies intended for oral, transdermal, subcutaneous, vaginal, or rectal administration. Authored by eminent scientists in academia and nonprofit organizations involved in the development of antiretroviral drug products, this collection provides useful information for all those involved in HIV/AIDS treatment and prevention.

Format
  • Paperback
License
© 2020 by the authors; CC BY-NC-ND license
Keywords
human immunodeficiency virus; acquired immunodeficiency syndrome; hematopoietic stem/progenitor cells; gene therapy; controlled release; ex vivo bioadhesion; Gelucire®; Human Immunodeficiency Virus; mucoadhesive vaginal compacts; Tenofovir; antiretroviral drugs; dendrimers; dosage forms; HIV prevention; mucosal drug delivery; nanocarriers; nanomedicine; nanoparticles; electrospun fibers; fiber architecture; drug delivery; intravaginal delivery; delivery vehicle; transdermal patch; tenofovir alafenamide; acrylate adhesive; in vitro permeation; silicone adhesive; suspension patch; microbicides; HIV; combination ARVs; sustained release; synergism; PLGA nanoparticles; co-delivery; HIV; antiretrovirals; nanoformulations; drug degradation; drug protection; suicide gene therapy; CRISPR/Cas9; broadly neutralizing antibodies; cytotoxic liposomes; lentivirus; poly(ε-caprolactone) (PCL); tenofovir alafenamide (TAF); pre-exposure prophylaxis (PrEP); long-acting drug delivery systems; implant; n/a